DarioHealth (NASDAQ:DRIO) Issues Earnings Results, Beats Estimates By $0.37 EPS

DarioHealth (NASDAQ:DRIO) released its quarterly earnings data on Tuesday. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.37, FiscalAI reports. The company had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.92 million. DarioHealth had a negative return on equity of 60.52% and a negative net margin of 192.23%.

Here are the key takeaways from DarioHealth’s conference call:

• Revenue declined to $5.2 million from $5.6 million in Q1 and $5.4 million a year ago, reflecting implementation timing and the company’s exit from pharmaceutical-services revenue. Management expects momentum to improve in Q3 and Q4, but most contracted revenue is not expected to contribute until 2027.
• DarioHealth ended Q2 with approximately $13.1 million in contracted and late-stage annual recurring revenue, more than 80% of it multi-condition, and reported over 180 signed employer and health-plan accounts. About 75% of new accounts now come through channel partners, which management says is reducing customer-acquisition costs and sales-cycle times.
• Financial efficiency improved, with gross margin rising to 62%, operating expenses falling 21% year over year, and net loss improving 39% to $7.9 million. Management expects incremental revenue from existing implementations, AI-enabled engagement, and new care offerings to generate meaningful operating leverage.
• The company launched an integrated GLP-1 program and introduced women’s health and sleep programs, expanding its provider-backed care and multi-condition platform. Dario expects DarioIQ to increase recurring revenue from existing customers by approximately 10%–15% over time through improved engagement, retention, and outcomes.
• Pro forma cash increased to $36.8 million following a July registered-direct financing, providing additional runway to execute on commercial opportunities and pursue the company’s path toward cash-flow positivity.

DarioHealth Stock Up 0.8%

Shares of NASDAQ DRIO traded up $0.07 during mid-day trading on Tuesday, hitting $7.72. The company had a trading volume of 37,387 shares, compared to its average volume of 15,220. The company has a market capitalization of $56.70 million, a PE ratio of -0.87 and a beta of 1.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62. DarioHealth has a 1-year low of $5.84 and a 1-year high of $17.74. The business’s 50-day simple moving average is $7.10 and its 200 day simple moving average is $8.33.

Insider Buying and Selling

In related news, Director Dennis Matheis purchased 14,430 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were bought at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the acquisition, the director directly owned 43,026 shares in the company, valued at $298,170.18. This trade represents a 50.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On DarioHealth

A number of institutional investors and hedge funds have recently made changes to their positions in DRIO. Kestra Advisory Services LLC purchased a new position in DarioHealth in the fourth quarter worth approximately $35,000. Geode Capital Management LLC increased its position in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after purchasing an additional 31,063 shares during the last quarter. Finally, XTX Topco Ltd increased its position in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after purchasing an additional 43,513 shares during the last quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DRIO has been the subject of a number of recent analyst reports. Stifel Nicolaus restated a “buy” rating and set a $10.00 price target on shares of DarioHealth in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Friday, July 10th. Finally, TD Cowen reaffirmed a “hold” rating and set a $11.00 target price on shares of DarioHealth in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.50.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.